Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Absci (ABSI) Current Deferred Revenue (2020 - 2025)

Absci (ABSI) has disclosed Current Deferred Revenue for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 7.53% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 7.53% year-over-year, with the annual reading at $1.2 million for FY2025, 7.53% up from the prior year.
  • Current Deferred Revenue hit $1.2 million in Q4 2025 for Absci, down from $1.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.1 million in Q4 2023 to a low of $300000.0 in Q3 2023.
  • Historically, Current Deferred Revenue has averaged $1.6 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest YoY gain for Current Deferred Revenue was 821.35% in 2023; the steepest drop was 85.67% in 2023.
  • Year by year, Current Deferred Revenue stood at $1.4 million in 2021, then crashed by 67.11% to $445000.0 in 2022, then soared by 821.35% to $4.1 million in 2023, then tumbled by 72.78% to $1.1 million in 2024, then grew by 7.53% to $1.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ABSI at $1.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.0 million in Q2 2025.